Longevity Biotech ("LongBio") and VC Diligence: Sebastian Brunemeier

Sebastian A. Brunemeier is a biotech founder focused on the biology of aging. He is CEO of ImmuneAGE Pharma, focused on rejuvenating the immune system. Sebastian was a Principal at Apollo Health Ventures, the first and largest aging-focused venture capital fund in the world, as well as Co-Founder and Chief Investment Officer at Cambrian Biopharma, a diversified drug discovery platform company focused on the biology of aging. Sebastian was founding CEO of Cyclone Therapeutics, a Scripps Research Institute spinout focused on proteostasis, and co-founder and COO of Samsara Therapeutics, focused on autophagy-enhancing small molecule drug discovery in Oxford, UK, which was recognized as ‘best startup’ at the Financial Times Pharma Conference. Prior to Apollo, he was a Fulbright Fellow in the biology of aging at the Gulbenkian Institute, awarded the Skaggs-Oxford fellowship at the Scripps Research Institute, and a SENS Foundation Scholar at the Buck Institute for Research on Aging. He was in the DPhil (PhD) program at Oxford as a Clarendon Scholar focusing on the biochemistry of aging, and received a joint MSc in Life Science Business Management and Molecular Neuroscience from the University of Amsterdam as an Amsterdam Excellence Scholar. He serves on the board of the clinical stage CNS pharmaceutical company Revivo Therapeutics, and served as a trustee of the British Society for Research on Aging and as an advisor to McKinsey & Company.